486 related articles for article (PubMed ID: 15619667)
1. Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44.
Cao JJ; Singleton PA; Majumdar S; Boudignon B; Burghardt A; Kurimoto P; Wronski TJ; Bourguignon LY; Halloran BP
J Bone Miner Res; 2005 Jan; 20(1):30-40. PubMed ID: 15619667
[TBL] [Abstract][Full Text] [Related]
2. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
[TBL] [Abstract][Full Text] [Related]
3. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.
Cao J; Venton L; Sakata T; Halloran BP
J Bone Miner Res; 2003 Feb; 18(2):270-7. PubMed ID: 12568404
[TBL] [Abstract][Full Text] [Related]
4. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
Kondo H; Guo J; Bringhurst FR
J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
[TBL] [Abstract][Full Text] [Related]
5. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines.
Nakashima T; Kobayashi Y; Yamasaki S; Kawakami A; Eguchi K; Sasaki H; Sakai H
Biochem Biophys Res Commun; 2000 Sep; 275(3):768-75. PubMed ID: 10973797
[TBL] [Abstract][Full Text] [Related]
6. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
Ikeda T; Utsuyama M; Hirokawa K
J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
[TBL] [Abstract][Full Text] [Related]
7. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
8. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
Koyama H; Nakade O; Takada Y; Kaku T; Lau KH
J Bone Miner Res; 2002 Jul; 17(7):1219-29. PubMed ID: 12096835
[TBL] [Abstract][Full Text] [Related]
9. TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis.
Abu-Amer Y; Abbas S; Hirayama T
J Cell Biochem; 2004 Nov; 93(5):980-9. PubMed ID: 15389885
[TBL] [Abstract][Full Text] [Related]
10. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
[TBL] [Abstract][Full Text] [Related]
11. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
12. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
[TBL] [Abstract][Full Text] [Related]
13. Human osteoblast precursors produce extracellular adenosine, which modulates their secretion of IL-6 and osteoprotegerin.
Evans BA; Elford C; Pexa A; Francis K; Hughes AC; Deussen A; Ham J
J Bone Miner Res; 2006 Feb; 21(2):228-36. PubMed ID: 16418778
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts.
Rifas L; Arackal S; Weitzmann MN
J Cell Biochem; 2003 Mar; 88(4):650-9. PubMed ID: 12577299
[TBL] [Abstract][Full Text] [Related]
15. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
[TBL] [Abstract][Full Text] [Related]
17. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells.
Hofbauer LC; Shui C; Riggs BL; Dunstan CR; Spelsberg TC; O'Brien T; Khosla S
Biochem Biophys Res Commun; 2001 Jan; 280(1):334-9. PubMed ID: 11162519
[TBL] [Abstract][Full Text] [Related]
18. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.
Wada N; Maeda H; Yoshimine Y; Akamine A
Bone; 2004 Sep; 35(3):629-35. PubMed ID: 15336598
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency.
Kanematsu M; Sato T; Takai H; Watanabe K; Ikeda K; Yamada Y
J Bone Miner Res; 2000 Jul; 15(7):1321-9. PubMed ID: 10893680
[TBL] [Abstract][Full Text] [Related]
20. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]